There have been two subsequent solid tumor studies of 9p21.3 loss (inferred from two genes on this band, CDKN2A and MTAP) reporting that 9p21.3 loss was associated with TME or ICT outcomes in lung adenocarcinoma, bladder cancer, melanoma, and small mixed solid tumor ICT cohorts (3, 22). This evidence concerns the gene CDKN2A and urinary bladder carcinoma.